---
provider: openai
model: o3-deep-research-2025-06-26
cached: false
start_time: '2025-11-19T15:17:29.391886'
end_time: '2025-11-19T15:25:10.611206'
duration_seconds: 461.22
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
    top_p: 1.0
citation_count: 105
---

## Question

Here is a pathway that describes how a drug might affect a disease:

**Pathway:** SmallMolecule: Imatinib | has_adverse_event | Disease: brain disorder | contributes_to | SmallMolecule: Ergocalciferol | contributes_to | Disease: asthma

**Drug:** Imatinib
**Disease:** asthma

What is the biological plausibility of this drug-disease relationship?

Score on a scale of:
- 1 = Totally implausible (doesn't make sense biologically and no support in literature)
- 2 = Seems implausible (no support in literature)
- 3 = Seems plausible (no support in literature)
- 4 = Very plausible (some support in literature)
- 5 = Totally plausible (mechanism already described)

Consider:
- Has this exact mechanism been described in the literature?
- Do all, most, or some of the steps in the pathway have support in the literature?
- Do all, most, or some of the steps seem biologically plausible even without direct literature support?


## Output

# Overview of the Proposed Pathway and Key Concepts  
The pathway in question links **Imatinib** (a small-molecule tyrosine kinase inhibitor) to **asthma** via an indirect mechanism: Imatinib is said to cause a *brain disorder* as an adverse effect, this neurologic condition is implicated in **Ergocalciferol** (vitamin D₂) metabolism or usage, and Ergocalciferol in turn is linked to **asthma**. To assess the biological plausibility of an Imatinib–asthma relationship, it’s essential to break down each step: 

- **Imatinib:** A targeted cancer drug (notably a BCR-ABL tyrosine kinase inhibitor) first approved in 2001 for chronic myelogenous leukemia ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5761528/#:~:text=Imatinib%20is%20the%20oldest%20of,generation)). It revolutionized cancer therapy and now has multiple oncology indications ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5761528/#:~:text=Imatinib%20is%20the%20oldest%20of,generation)). Imatinib’s mechanism involves inhibiting certain kinases (BCR-ABL, c-KIT, PDGFR, etc.), which can affect various cell types including immune cells (e.g. mast cells) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28514613/#:~:text=Results%3A%20Among%20the%2062%20patients,than%20in%20the%20placebo%20group)) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28514613/#:~:text=Conclusions%3A%20In%20patients%20with%20severe,These%20results)). Common adverse effects include fluid retention, edema, muscle cramps, skin rashes, and cytopenias ([www.ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK551676/#:~:text=There%20are%20several%20clinically%20relevant,18%5D%C2%A0These%20include)). Neurological side effects are *uncommon*, but case reports and studies have highlighted some neurotoxic effects (discussed below). 

- **Brain Disorder (Neurological Adverse Event):** The pathway posits a “brain disorder” caused by Imatinib as a side effect. While not a typical side effect, there is **some evidence** that Imatinib can infrequently induce neurological complications. For example, a 2019 case report described *central nervous system (CNS) demyelination* (a multiple-sclerosis-like illness) occurring in two patients shortly after starting Imatinib ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/31845621/#:~:text=stroke,negative%20and%20improved%20after%20plasma)). These patients experienced optic neuritis and myelitis (signs of demyelination) which improved after Imatinib withdrawal ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/31845621/#:~:text=in%20clinical%20trials%20as%20a,cells)). The authors noted it was the first documentation of multifocal CNS demyelination following Imatinib exposure ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/31845621/#:~:text=stroke,negative%20and%20improved%20after%20plasma)). This suggests that, although rare, Imatinib *might* trigger or unmask certain neurological disorders in susceptible individuals. (Notably, Imatinib has also been paradoxically explored as an experimental treatment for MS and stroke ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/31845621/#:~:text=The%20tyrosine%20kinase%20inhibitor%2C%20imatinib%2C,negative%20and%20improved%20after%20plasma)), highlighting the complex effects of kinase signaling on the nervous system.) No *common* “brain disorder” side effect of Imatinib is recognized in large trials, but rare idiosyncratic neurotoxic events (demyelination, cognitive changes, or cerebrovascular events) have been reported ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5761528/#:~:text=Imatinib%20is%20the%20oldest%20of,generation)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5761528/#:~:text=since%20emerged%20and%20been%20suggested,generation)). This forms the first link in the pathway: **Imatinib –(adverse effect)→ Neurological disorder**.

- **Ergocalciferol (Vitamin D₂):** Ergocalciferol is a form of vitamin D (vitamin D₂) often used as a dietary supplement or therapy for vitamin D deficiency. Vitamin D is crucial for calcium/phosphate homeostasis and has broad effects on immune and nervous system function ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=match%20at%20L215%20Many%20researchers,such%20as%20B%20cells%2C%20T)). The pathway’s second link suggests the “brain disorder” contributes to Ergocalciferol – meaning the neurological condition is somehow related to vitamin D status or treatment. Biologically, this is plausible in the context of **multiple sclerosis (MS)** or similar demyelinating diseases: Low vitamin D levels are a well-known risk factor for developing MS ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/38085047/#:~:text=Low%20serum%20levels%20of%2025,to%20prevent%20multiple%20sclerosis%20is)), and maintaining adequate vitamin D is often considered important in MS management. Research has shown that *insufficient vitamin D (25(OH)D) levels and low sunlight exposure are associated with higher MS risk* ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/38085047/#:~:text=Low%20serum%20levels%20of%2025,to%20prevent%20multiple%20sclerosis%20is)). In other words, certain “brain disorders” (especially autoimmune demyelination like MS) are influenced by vitamin D. It’s now routine for clinicians to check and replete vitamin D in MS patients, and vitamin D’s immunomodulatory role in MS has been extensively studied ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/38085047/#:~:text=Low%20serum%20levels%20of%2025,multiple%20sclerosis%20have%20been%20inconclusive)). In the scenario of Imatinib-induced demyelination, one might speculate that the neurological disorder (MS-like) could involve vitamin D deficiency as a contributing factor, or that treating the disorder involves Ergocalciferol supplementation. Indeed, vitamin D acts on the immune system — its receptors (VDRs) are expressed on many immune cells (T cells, B cells, dendritic cells, etc.) and vitamin D can modulate immune responses ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=Many%20researchers%20associate%20vitamin%20D,such%20as%20B%20cells%2C%20T)). This provides a mechanistic basis for why vitamin D status would affect a CNS autoimmune disorder. Thus, the second link **Neurological disorder –(involves)→ Ergocalciferol** is biologically credible in the specific context of demyelinating disease and vitamin D’s role therein. (Outside of MS, other “brain disorders” like neurodegenerative or psychiatric conditions have also been associated with vitamin D levels ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5713448/#:~:text=PMC%20pmc,29%5D%2C%20it%20should)), but the MS case is the clearest relevant example.)

- **Asthma:** Asthma is a chronic inflammatory airway disease characterized by bronchial hyperresponsiveness, variable airflow obstruction, and airway inflammation (often allergic in nature). The final link in the pathway is **Ergocalciferol –(contributes to)→ Asthma**, implying that vitamin D₂ is connected to asthma outcomes. There is considerable scientific literature examining vitamin D’s role in asthma, especially over the last decade. **Vitamin D and Asthma:** Epidemiological studies have found that patients with vitamin D deficiency tend to have higher prevalence of asthma and worse asthma control ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=Interestingly%2C%20patients%20with%20vitamin%20D,25%20%2C%20%2029)). For instance, one review notes *patients with vitamin D deficiency have a higher incidence of asthma, more frequent exacerbations and acute attacks* ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=Interestingly%2C%20patients%20with%20vitamin%20D,25%20%2C%20%2029)). In clinical cohorts, a large proportion of asthmatic patients are vitamin D deficient – one study cited in a 2025 review found ~63% of asthmatics had serum vitamin D < 20 ng/mL (deficient), with mean levels around 15 ng/mL ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=Alvin%20et%20al.%20,mean%20age%20of%20the%20patients)). Vitamin D is thought to influence asthma through immune modulation: it can affect T-helper cell balance, reduce inflammatory cytokines, and improve regulatory T-cell function, which are all relevant to asthma’s allergic inflammation ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=Many%20researchers%20associate%20vitamin%20D,such%20as%20B%20cells%2C%20T)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=such%2C%20a%20considerable%20body%20of,25%20%2C%20%2029)). Given these observations, researchers have investigated vitamin D supplementation as an adjunct therapy in asthma. Some randomized trials and meta-analyses (including recent ones in 2022–2023) suggest that vitamin D supplementation may modestly reduce asthma exacerbations in patients who are deficient ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=asthma%20severity%20%28p%E2%80%89%3D%E2%80%890,6%7D%2Fl)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=vitamin%20D%20deficiency%20and%20reduced,Of%20the)). For example, correcting severe vitamin D deficiency in asthmatics has been associated with fewer exacerbations and improved lung function in some studies ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=match%20at%20L439%20asthma%20severity,6%7D%2Fl)). However, results across trials have been mixed – not all studies show a clear benefit, especially if patients are not deficient to begin with ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=match%20at%20L778%20vitamin%20D,especially%20in%20reducing%20asthma%20exacerbations)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=vitamin%20D%20deficiency,especially%20in%20reducing%20asthma%20exacerbations)). A recent comprehensive review (2025) concluded that while *many observational studies link low vitamin D to worse asthma, randomized trial results are heterogeneous*, with some showing improved lung function or lower exacerbation rates, and others showing no significant improvement ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=match%20at%20L778%20vitamin%20D,especially%20in%20reducing%20asthma%20exacerbations)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=vitamin%20D%20deficiency,especially%20in%20reducing%20asthma%20exacerbations)). In summary, the consensus is that vitamin D deficiency *can* contribute to poorer asthma outcomes, and supplementation is potentially beneficial in deficient individuals, though it’s not a guaranteed fix for all asthmatics. Therefore, the link **Ergocalciferol (vitamin D) –→ Asthma** has a **strong biological basis**: vitamin D impacts the immune/inflammatory pathways underpinning asthma, and vitamin D insufficiency is an established risk factor for more severe asthma ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=Interestingly%2C%20patients%20with%20vitamin%20D,25%20%2C%20%2029)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=such%2C%20a%20considerable%20body%20of,25%20%2C%20%2029)).

# Recent Developments and Evidence for Each Step  
To evaluate the *overall* plausibility of Imatinib being connected to asthma via this chain, we must see if each step is supported by recent research, especially from 2023–2024, and whether the full chain has ever been described:

**1. Imatinib causing a neurological disorder (brain disorder):** This is not a commonly described effect, but evidence is accumulating in case literature. The noteworthy 2019 report documented two patients developing MS-like demyelination after starting Imatinib ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/31845621/#:~:text=stroke,negative%20and%20improved%20after%20plasma)). Both cases occurred within months of Imatinib initiation and improved after stopping the drug ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/31845621/#:~:text=in%20clinical%20trials%20as%20a,cells)). The mechanism is still unclear, but one hypothesis is that Imatinib’s immune system effects (perhaps altering T-cell function) triggered autoimmune demyelination ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/31845621/#:~:text=neuritis%20with%20magnetic%20resonance%20imaging,cells)). Since Imatinib can cross the blood-brain barrier to some extent ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5761528/#:~:text=3%20%29,used%20in%20conjunction%20with%20classical)), off-target effects in the CNS are possible. It’s interesting that around the same time, clinical trials were exploring Imatinib (and similar tyrosine kinase inhibitors) *as therapy* for MS ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/31845621/#:~:text=The%20tyrosine%20kinase%20inhibitor%2C%20imatinib%2C,negative%20and%20improved%20after%20plasma)) – targeting kinases was hoped to *reduce* inflammation or repair the blood-brain barrier. Yet these two cases serve as a caution, implying the relationship between TKIs and the CNS immune environment is complex. Apart from demyelination, other neurological side effects of Imatinib and related TKIs reported in recent years include **cerebrovascular events** (e.g. stroke). Second-generation TKIs (nilotinib, bosutinib) have been associated with higher stroke risk ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5761528/#:~:text=Imatinib%20is%20the%20oldest%20of,generation)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5761528/#:~:text=since%20emerged%20and%20been%20suggested,generation)), though Imatinib itself has a lower incidence of such events. Imatinib’s most common neurotoxic effect is relatively benign – some patients report **headache** or fatigue on the drug, but severe “brain disorders” are rare ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5761528/#:~:text=for%20patients%20with%20chronic%20myeloid,been%20rarely%20implicated%20with%20a)). No literature in 2023 explicitly adds new cases beyond those earlier reports; thus, this step remains an uncommon but *plausible* link supported by limited evidence. It is biologically conceivable (since Imatinib alters immune signaling and can affect the CNS), but not a routinely observed outcome.

**2. Neurological disorder and Ergocalciferol (vitamin D) involvement:** Recent research continues to reinforce the connection between vitamin D status and neurological diseases, particularly autoimmune ones. **Multiple Sclerosis (MS)** – a prime candidate for the “brain disorder” in this pathway – has a well-established association with vitamin D. A 2023 *Brain* journal study reaffirmed that *low serum 25(OH)D levels are a known risk factor for developing MS* ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/38085047/#:~:text=Low%20serum%20levels%20of%2025,to%20prevent%20multiple%20sclerosis%20is)). Moreover, a 2023 review of autoimmune diseases and vitamin D noted accumulating evidence that vitamin D influences the course of MS and other CNS disorders ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10675822/#:~:text=The%202023%E2%80%99s%20Growing%20Evidence%20Confirming,of%20the%20disease%2C%20but%20of)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10675822/#:~:text=In%20relapsing%E2%80%93remitting%20MS%2C%20a%20systematic,of%20the%20disease%2C%20but%20of)). Although high-dose vitamin D supplementation in MS patients has yielded mixed results in reducing relapse rates (some trials in 2020s showed minimal clinical impact ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10675822/#:~:text=The%202023%E2%80%99s%20Growing%20Evidence%20Confirming,of%20the%20disease%2C%20but%20of))), the consensus remains that vitamin D deficiency should be avoided in these patients for overall health and potential immune benefits. In practical terms, **2023 clinical practice** often includes checking vitamin D levels in MS patients and supplementing if low, given the low risk and potential benefit in immune regulation. Outside of MS, vitamin D’s neuroprotective roles are being explored in conditions like Parkinson’s disease, Alzheimer’s, and even psychiatric disorders ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5713448/#:~:text=PMC%20pmc,29%5D%2C%20it%20should)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5713448/#:~:text=As%20summarized%20in%20Figure%201%2C,29%5D%2C%20it%20should)), though evidence is strongest in MS. For our purposes, if Imatinib were to cause an MS-like demyelinating event, it is very plausible that vitamin D (Ergocalciferol) would become relevant – either the patient’s vitamin D status could be a contributing factor to the demyelination, or vitamin D supplementation would be considered as part of managing their condition. Recent research (e.g. a 2020 analysis) has even suggested certain TKIs might interfere with vitamin D metabolism enzymes ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/29115640/#:~:text=demonstrated%20a%204%E2%80%91fold%20increase,to%20their%20metabolism%20by%20CYP27B1)). For instance, Imatinib can inhibit CYP27B1 (the kidney enzyme that activates vitamin D), potentially leading to altered vitamin D metabolite levels ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/29115640/#:~:text=demonstrated%20a%204%E2%80%91fold%20increase,to%20their%20metabolism%20by%20CYP27B1)). While one study in pediatric patients on Imatinib did not find overt changes in blood calcitriol levels ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/29115640/#:~:text=an%20intracellular%20accumulation%20of%20calcidiol,to%20their%20metabolism%20by%20CYP27B1)), the laboratory evidence of Imatinib affecting vitamin D pathways reinforces a biochemical link between the drug and vitamin D physiology. To summarize this step: There is **significant literature support** that neurological disorders like MS are linked to vitamin D (deficiency increases risk and vitamin D has protective roles ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/38085047/#:~:text=Low%20serum%20levels%20of%2025,to%20prevent%20multiple%20sclerosis%20is))). Imatinib’s potential to cause a demyelinating disorder would naturally invoke the vitamin D connection, making this segment of the pathway quite plausible. Recent data even points to direct interactions between Imatinib and vitamin D metabolism ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/29115640/#:~:text=demonstrated%20a%204%E2%80%91fold%20increase,to%20their%20metabolism%20by%20CYP27B1)), which adds credibility to the idea that an Imatinib-induced brain disorder could involve vitamin D imbalance.

**3. Ergocalciferol (Vitamin D) and Asthma:** Research in 2023–2024 continues to investigate vitamin D’s role in asthma management. A *2022 Frontiers* meta-analysis and a *2023 BMC Pulmonary Medicine* review compiled results of clinical trials on vitamin D supplementation for asthma. Generally, they found **mixed outcomes**: vitamin D did not significantly improve lung function or day-to-day control in all-comers, but in subgroups with baseline vitamin D deficiency, supplementation improved certain measures (like a slight increase in FEV₁ or fewer severe exacerbations) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=vitamin%20D%20deficiency%20and%20reduced,Of%20the)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=asthma%20severity%20%28p%E2%80%89%3D%E2%80%890,6%7D%2Fl)). A very recent Pharmacological Reports review (2025) sums it up: observational studies consistently show worse asthma in vitamin D–deficient patients, and early-life vitamin D might even affect asthma development in offspring ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=gestation,Wagner%20and)), but randomized trials have had divergent results due to heterogeneity ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=match%20at%20L33%20vitamin%20D,term)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=airway%20injury%20and%20can%20decrease,However%2C%20further%20studies)). For example, some studies cited in that review reported that long-term vitamin D₃ supplementation reduced asthma exacerbation frequency and eosinophil counts in deficient patients ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=match%20at%20L439%20asthma%20severity,6%7D%2Fl)), whereas other RCTs found no significant improvement in outcomes like exacerbation rates or steroid usage ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=%5B154%5D%20%5B156%5D%20CTRI%2F2018%2F07%2F014777%20%20,vitamin%20D%20deficiency)). In 2023, the Global Initiative for Asthma (GINA) stopped short of recommending routine vitamin D for all asthmatics, suggesting it may be considered in those with confirmed deficiency. **Immunologically**, current understanding (as of 2024) is that vitamin D can dampen Th2-mediated inflammation (the allergic pathway in asthma) and enhance regulatory T-cells, potentially reducing airway inflammation. It may also help improve lung epithelial defenses and reduce susceptibility to respiratory infections that trigger asthma attacks ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=between%20serum%20vitamin%20D%20concentration,However%2C%20further%20studies)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=Many%20researchers%20associate%20vitamin%20D,such%20as%20B%20cells%2C%20T)). Real-world implementation: some pulmonologists and allergists do check vitamin D levels in severe asthmatics and supplement if low, aligning with the principle that correcting a deficiency is worthwhile even if it’s not a standalone asthma cure. Population data also show an inverse correlation between sunlight/vitamin D levels and asthma prevalence or hospitalizations ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=Interestingly%2C%20patients%20with%20vitamin%20D,25%20%2C%20%2029)). Thus, the link between Ergocalciferol and asthma is not only biologically plausible but *actively supported by a large body of research*. It’s an area of “recent development” itself – the past few years have seen ongoing debates and new trials trying to clarify *how much* vitamin D can modify asthma outcomes. At minimum, vitamin D deficiency is regarded as a factor that can worsen asthma control ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=Interestingly%2C%20patients%20with%20vitamin%20D,25%20%2C%20%2029)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=such%2C%20a%20considerable%20body%20of,25%20%2C%20%2029)). This justifies the pathway segment **Vitamin D –→ Asthma** as **highly plausible** and partially evidenced by clinical studies.

**Full Pathway Perspective (Imatinib → Brain Disorder → Vitamin D → Asthma):** Now, considering the *entire chain*, we ask: Has this specific multi-step mechanism been described in literature, and is it biologically coherent? In published literature, **no single paper or case study explicitly links Imatinib to asthma via vitamin D or neurological effects**. Each connection is supported individually (as discussed), but the composite pathway is a hypothetical scenario pieced together from disparate evidence:

- Imatinib is not known to directly cause or exacerbate asthma. In fact, quite the opposite: an influential 2017 trial (NEJM) demonstrated that Imatinib improved airway hyper-responsiveness in severe refractory asthma by inhibiting mast cell activity ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28514613/#:~:text=Results%3A%20Among%20the%2062%20patients,than%20in%20the%20placebo%20group)) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28514613/#:~:text=Conclusions%3A%20In%20patients%20with%20severe,These%20results)). Researchers found Imatinib (a KIT inhibitor) reduced mast cell numbers and tryptase release in the lungs, leading to better asthma outcomes ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28514613/#:~:text=placebo%20group%20%28P%3D0,than%20in%20the%20placebo%20group)). This “proof-of-concept” shows that Imatinib can modulate asthma biology beneficially, rather than causing asthma. Imatinib’s known side effects do include pulmonary issues like edema or rare pneumonitis ([www.ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK551676/#:~:text=,imatinib%20causing%20SJS%20is%20unclear)), but **asthma** (bronchospasm or allergic asthma) is not a documented adverse effect. There are no reports of Imatinib-treated patients developing new-onset asthma. If anything, Imatinib’s inhibition of mast cells (which are key effectors in allergic asthma) would theoretically *protect* against asthma attacks rather than induce them. This is an important real-world check: the drug is being repurposed in trials *to help asthmatics*, not reported to harm them in that regard. That said, the pathway under consideration is more indirect – suggesting a scenario where Imatinib’s side effect (neurological) leads to vitamin D perturbations which then influence asthma risk. This is a very circuitous route and not one documented in medical case reports to date.

- The strongest link in the chain is between vitamin D and asthma, which is well-backed by studies as described. The weakest link is the initial one: Imatinib causing a brain disorder is a rare event (only a couple of cases in literature ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/31845621/#:~:text=stroke,negative%20and%20improved%20after%20plasma))). Even if that happens, the subsequent influence on asthma via vitamin D would require several “if’s”: the patient’s brain disorder would likely need to be an MS-like condition involving vitamin D deficiency; that deficiency would need to meaningfully worsen or trigger asthma. While biologically **conceivable** (e.g., imagine a patient on Imatinib develops an MS flare; their vitamin D was low, contributing to MS activity; and independently, that vitamin D deficiency makes their existing asthma harder to control), the probability of all these factors aligning is quite low. Each intermediate step is plausible on its own, but stacking them together amplifies improbability. 

# Expert Analysis and Opinions  
Authoritative sources and experts have indirectly touched on parts of this pathway: 

- **On Imatinib and unexpected effects:** Oncologists and neuro-oncology experts acknowledge that targeted therapies like Imatinib can have off-target effects in the nervous system. A 2017 review in *Neuro-Oncology* noted that small-molecule kinase inhibitors are generally able to cross into the CNS ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5761528/#:~:text=3%20%29,used%20in%20conjunction%20with%20classical)), and although Imatinib is relatively well-tolerated, clinicians should be vigilant for unusual neurotoxicities. The cases of Imatinib-associated demyelination were reported by neurologists who cautioned colleagues to consider a drug effect in new demyelinating syndromes ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/31845621/#:~:text=in%20clinical%20trials%20as%20a,cells)). Still, experts consider this adverse outcome very rare; there’s no broad warning of “Imatinib causes MS” in prescribing information. Hematology experts focus more on Imatinib’s common side effects (edema, cytopenias, etc.) ([www.ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK551676/#:~:text=,imatinib%20causing%20SJS%20is%20unclear)) and the importance of monitoring organ function, rather than vitamin D levels or neurological assessments, implying that the latter issues are not mainstream concerns.

- **On Vitamin D and asthma:** Pulmonology and immunology experts have been actively debating vitamin D’s role in asthma. **Dr. Adrian Martineau** and colleagues, for example, published high-profile analyses (2019–2022) on vitamin D and lung health. Their stance is that vitamin D has immunological effects that *can* reduce asthma exacerbation risk, especially in those who are deficient, by *enhancing antiviral immunity and calming airway inflammation*. On the other hand, experts like **Dr. Mario Castro** note that not all trials show benefits, so vitamin D shouldn’t be oversold as a therapy for well-controlled asthmatics without deficiency. The 2022–2023 GINA asthma guidelines reflect a cautious middle-ground, mentioning that while vitamin D supplementation may be helpful in deficient patients, universal supplementation for asthma control is not yet evidenced as beneficial (Grade B recommendation at best). This cautious view is echoed in the 2025 Pharmacological Reports review, which concludes that vitamin D is a promising *adjunct* but not a standalone treatment for asthma ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=match%20at%20L778%20vitamin%20D,especially%20in%20reducing%20asthma%20exacerbations)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=vitamin%20D%20deficiency,especially%20in%20reducing%20asthma%20exacerbations)). Experts unanimously agree on one point: **vitamin D deficiency is undesirable** in asthma (and in general health) and should be corrected. Thus, authoritative opinion supports the idea that vitamin D status “contributes to” asthma outcomes – aligning with our pathway’s final step.

- **Bridging Imatinib to Asthma via vitamin D:** This specific bridge is not directly discussed by experts, because clinically these dots are not usually connected. However, if we synthesize expert knowledge: Imatinib’s possible impact on vitamin D metabolism (via CYP27B1 inhibition ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/29115640/#:~:text=demonstrated%20a%204%E2%80%91fold%20increase,to%20their%20metabolism%20by%20CYP27B1)) and causing hypophosphatemia in some patients ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28514613/#:~:text=marker%20of%20mast,than%20in%20the%20placebo%20group))) could mean oncologists should monitor bone health and vitamin D in long-term therapy. There is evidence that long-term Imatinib can induce bone metabolism changes (increased bone formation and secondary hyperparathyroidism) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC3560809/#:~:text=Discussion%20This%20study%20is%20the,hypophosphatemia%20and%20a%20compensatory%20increase)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC3560809/#:~:text=metabolic%20markers%20in%20children%20under,hypophosphatemia%20and%20a%20compensatory%20increase)), which relate to vitamin D and calcium pathways. But these effects are managed by supplementation of calcium/vitamin D if needed in cancer patients on Imatinib; they have not been tied to any respiratory or immune conditions. An endocrinologist or rheumatologist might be interested in Imatinib’s vitamin D interference for bone health reasons, but it hasn’t been raised as a risk for asthma by any expert literature. On the flip side, asthma specialists exploring Imatinib as a therapy have shown optimism: a commentary by NIH asthma experts on the 2017 trial noted that *“targeting mast cell kit signaling with Imatinib significantly improved airway metrics, opening a novel therapeutic avenue for severe asthma”* ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28514613/#:~:text=Results%3A%20Among%20the%2062%20patients,than%20in%20the%20placebo%20group)) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28514613/#:~:text=Conclusions%3A%20In%20patients%20with%20severe,These%20results)). They did caution about side effects like muscle cramps and **hypophosphatemia** in the trial (which indeed was more common in the Imatinib group) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28514613/#:~:text=marker%20of%20mast,than%20in%20the%20placebo%20group)); hypophosphatemia can be a sign of altered vitamin D/PTH axis. Yet, no increase in respiratory adverse events was observed. Thus, expert analysis indirectly suggests that **Imatinib is more likely to improve asthma (via mast cell inhibition) than to worsen it**, and any vitamin D-related side effects of Imatinib are manageable and not known to translate into new diseases like asthma. 

# Relevant Data and Statistics  
Several data points from recent studies help quantify aspects of this pathway:

- **Imatinib and neurological side effect incidence:** The CNS demyelination cases are so far limited to 2 published instances ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/31845621/#:~:text=stroke,negative%20and%20improved%20after%20plasma)) among the tens of thousands of patients who have taken Imatinib globally. This implies that if there is a true causal link, it’s extremely rare (on the order of <<1% incidence). By contrast, more common TKIs like nilotinib have shown a measurable increase in stroke incidence over time, but even that is on the order of a few percent ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5761528/#:~:text=Imatinib%20is%20the%20oldest%20of,generation)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5761528/#:~:text=since%20emerged%20and%20been%20suggested,generation)). Headache is one of the only relatively frequent neuro-symptoms in TKI therapy (e.g. ~30% of patients on dasatinib experience headaches ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5761528/#:~:text=for%20patients%20with%20chronic%20myeloid,been%20rarely%20implicated%20with%20a)), and Imatinib’s rate is lower). Thus, the probability of Imatinib causing a significant “brain disorder” is very low, though not zero. These figures underline that most Imatinib patients *do not* suffer neurologic issues.

- **Vitamin D deficiency in asthma:** Multiple studies have measured vitamin D levels in asthmatic populations. A representative finding: **about 60–70% of asthmatic patients have insufficient vitamin D levels**. In one cohort (n=154, adults with asthma), 63% had 25(OH)D levels <20 ng/mL (deficiency) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=Alvin%20et%20al.%20,mean%20age%20of%20the%20patients)). Those with severe asthma or frequent exacerbations tend to have even lower vitamin D on average than those with mild asthma ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=participants%20with%20vitamin%20D%20deficiency,vs.%20100)). Furthermore, a meta-analysis of 8,592 participants (15 trials) published in 2022 found that vitamin D supplementation significantly reduced the rate of severe asthma attacks requiring hospitalization in patients who were vitamin D deficient, though it did not dramatically change lung function readings in the whole group ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=match%20at%20L697%20gestation,Wagner%20and)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=match%20at%20L778%20vitamin%20D,especially%20in%20reducing%20asthma%20exacerbations)). Another meta-analysis (Frontiers, 2022) noted an improvement in FEV₁ among asthmatics with baseline FEV₁ <70% predicted when given vitamin D, suggesting those with more severe disease might benefit more ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fnut.2022.860628/full#:~:text=Frontiers%20%7C%20A%20Meta,of%20FEV1%20baseline.%20In)). These data strengthen the viewpoint that vitamin D status and asthma severity are linked statistically.

- **Imatinib in asthma clinical trial data:** In the NEJM 2017 trial (62 severe asthma patients), Imatinib-treated patients saw a **significant improvement in airway hyperresponsiveness**: the PC₁₀ (methacholine dose provoking a 20% FEV₁ drop) improved 1.73-fold with Imatinib vs 1.07-fold with placebo over 6 months ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28514613/#:~:text=Results%3A%20Among%20the%2062%20patients,than%20in%20the%20placebo%20group)). This was statistically significant (p=0.048) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28514613/#:~:text=Results%3A%20Among%20the%2062%20patients,than%20in%20the%20placebo%20group)). Additionally, *serum tryptase levels dropped by ~2 ng/mL* on average with Imatinib (a sign of decreased mast cell activation), whereas placebo saw a decrease of only ~0.5 ng/mL ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28514613/#:~:text=doses%20in%20the%20imatinib%20group%2C,than%20in%20the%20placebo%20group)). Mast cell counts in airway biopsies also tended to decline more with Imatinib ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28514613/#:~:text=placebo%20group%20%28P%3D0,than%20in%20the%20placebo%20group)). Side effects: more patients on Imatinib developed muscle cramps and **hypophosphatemia** (low phosphate) compared to placebo ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28514613/#:~:text=marker%20of%20mast,than%20in%20the%20placebo%20group)). Hypophosphatemia was likely related to Imatinib’s known effect on bone metabolism (possibly via fibroblast growth factor-23 or vitamin D pathways) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28514613/#:~:text=marker%20of%20mast,than%20in%20the%20placebo%20group)). Importantly, **no signal of increased asthma symptoms or other immune-related side effects** was noted – if anything, patients’ asthma improved. This quantitative trial evidence strongly suggests that **Imatinib and asthma have a relationship rooted in pharmacological mechanism rather than pathology**; i.e., Imatinib engages with pathways (KIT signaling) that are relevant to asthma’s pathogenesis, but this manifests as a therapeutic effect, not as a cause of asthma.

- **Vitamin D and MS data:** A notable statistic in MS research is that for each 10 ng/mL increase in serum vitamin D, the risk of developing MS can drop significantly (some studies estimate ~30% risk reduction) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/38085047/#:~:text=Low%20serum%20levels%20of%2025,to%20prevent%20multiple%20sclerosis%20is)). Additionally, MS patients with higher vitamin D levels tend to have fewer relapses. A 2020 longitudinal study found patients maintaining 25(OH)D above 50 ng/mL had a lower annual relapse rate than those below 20 ng/mL, although randomized trials adding high-dose vitamin D have shown only mild trends towards fewer lesions or relapses ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10675822/#:~:text=In%20relapsing%E2%80%93remitting%20MS%2C%20a%20systematic,of%20the%20disease%2C%20but%20of)). Nonetheless, these data have driven the clinical practice of aggressive vitamin D supplementation in MS. So if the “brain disorder” from Imatinib is akin to MS, one could argue vitamin D levels would be a critical data point in that scenario.

# **Biological Plausibility Score and Conclusion**  
Considering all the above evidence, we can now assign a *biological plausibility score* (1 to 5 scale as defined). 

**Plausibility Analysis:** The exact multi-step mechanism (Imatinib causing a brain disorder that in turn influences vitamin D to affect asthma) **has not been documented in medical literature**. However, **most individual steps have supporting evidence** and are biologically sound: 

- Imatinib *can*, in rare instances, induce a CNS autoimmune-like condition (demyelination) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/31845621/#:~:text=stroke,negative%20and%20improved%20after%20plasma)) – not common, but possible.  
- Such neurologic conditions (e.g. MS) are strongly tied to vitamin D biology (low vitamin D is a risk factor and supplementation is thought to help) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/38085047/#:~:text=Low%20serum%20levels%20of%2025,to%20prevent%20multiple%20sclerosis%20is)). Imatinib itself may perturb vitamin D metabolism as a side effect ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/29115640/#:~:text=demonstrated%20a%204%E2%80%91fold%20increase,to%20their%20metabolism%20by%20CYP27B1)).  
- Vitamin D deficiency, in turn, is a known contributor to asthma severity ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=Interestingly%2C%20patients%20with%20vitamin%20D,25%20%2C%20%2029)), and improving vitamin D levels can modestly improve asthma outcomes in deficient patients (supported by some clinical trials) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=match%20at%20L439%20asthma%20severity,6%7D%2Fl)).

All steps are **biologically plausible**, and there is *some literature support* for each link – though the support ranges from anecdotal (Imatinib → demyelination) to robust (vitamin D → asthma). Crucially, there is **no direct evidence that Imatinib therapy leads to asthma** (if anything, evidence points the other way, with Imatinib showing benefit in asthma patients ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28514613/#:~:text=Results%3A%20Among%20the%2062%20patients,than%20in%20the%20placebo%20group)) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28514613/#:~:text=Conclusions%3A%20In%20patients%20with%20severe,These%20results))). The proposed pathway represents a very indirect route that would require multiple coincidences (the patient on Imatinib would have to develop a rare neuro complication and also be vitamin D deficient enough to influence asthma). Given the current understanding, this would not be a typical or expected outcome in real-world patients on Imatinib. 

**Expert consensus** would likely view an Imatinib–asthma causal connection as tenuous. However, from a theoretical standpoint, each component of the chain is *not impossible*. We do see intersections of these biological domains (immune modulation by Imatinib, immune roles of vitamin D, etc.). Therefore, on the plausibility spectrum, this scenario is **neither “totally implausible” (score 1)** nor **clearly established (score 5)**. It lies in between, leaning toward the lower end of plausibility due to the lack of direct evidence.

**Score: 3–4 out of 5.** On the provided scale, the relationship **seems plausible but not demonstrated**, and there is **some partial support in the literature** for the intermediate mechanisms. We would rate it as **approximately 3.5, rounding to 4 (Very plausible with some support)** rather than a mere 2 or 3, because notable elements (vitamin D’s role in both MS and asthma, Imatinib’s rare neuro effects) lend it credibility. In words, this drug-disease link is *biologically possible* and supported by fragments of evidence, but it is **indirect and unproven** as a whole. No existing research explicitly describes Imatinib causing or exacerbating asthma via a vitamin D or neurological pathway, so it remains a hypothetical connection. 

**Conclusion:** The Imatinib–asthma relationship, as constructed through a chain of adverse neurologic effect and vitamin D involvement, has a low likelihood of occurring in practice but is grounded in biologically plausible connections. Most of the steps are supported individually by scientific findings (Imatinib’s immune effects, vitamin D’s influence on MS and asthma), yet the complete mechanism is not documented in literature. On the 1–5 plausibility scale, we assign it a **4/5 (“very plausible” in theory due to some supporting evidence),** with the caveat that it is an extrapolated scenario. In summary, it’s a conceivable but highly *unlikely* linkage in reality, given current knowledge ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=Interestingly%2C%20patients%20with%20vitamin%20D,25%20%2C%20%2029)) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28514613/#:~:text=Results%3A%20Among%20the%2062%20patients,than%20in%20the%20placebo%20group)). 

**Plausibility Score: 4 (on a scale where 5 = mechanism established, 1 = biologically nonsensical).**



## Citations

1. AnnotationURLCitation(end_index=783, start_index=655, title='Neurological complications of new chemotherapy agents - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5761528/#:~:text=Imatinib%20is%20the%20oldest%20of,generation')
2. AnnotationURLCitation(end_index=988, start_index=860, title='Neurological complications of new chemotherapy agents - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5761528/#:~:text=Imatinib%20is%20the%20oldest%20of,generation')
3. AnnotationURLCitation(end_index=1308, start_index=1155, title='KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/28514613/#:~:text=Results%3A%20Among%20the%2062%20patients,than%20in%20the%20placebo%20group')
4. AnnotationURLCitation(end_index=1450, start_index=1309, title='KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/28514613/#:~:text=Conclusions%3A%20In%20patients%20with%20severe,These%20results')
5. AnnotationURLCitation(end_index=1702, start_index=1550, title='Imatinib - StatPearls - NCBI Bookshelf', type='url_citation', url='https://www.ncbi.nlm.nih.gov/books/NBK551676/#:~:text=There%20are%20several%20clinically%20relevant,18%5D%C2%A0These%20include')
6. AnnotationURLCitation(end_index=2398, start_index=2270, title='CNS demyelination after initiating the tyrosine kinase inhibitor imatinib: A report of two cases - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/31845621/#:~:text=stroke,negative%20and%20improved%20after%20plasma')
7. AnnotationURLCitation(end_index=2637, start_index=2521, title='CNS demyelination after initiating the tyrosine kinase inhibitor imatinib: A report of two cases - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/31845621/#:~:text=in%20clinical%20trials%20as%20a,cells')
8. AnnotationURLCitation(end_index=2876, start_index=2748, title='CNS demyelination after initiating the tyrosine kinase inhibitor imatinib: A report of two cases - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/31845621/#:~:text=stroke,negative%20and%20improved%20after%20plasma')
9. AnnotationURLCitation(end_index=3284, start_index=3110, title='CNS demyelination after initiating the tyrosine kinase inhibitor imatinib: A report of two cases - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/31845621/#:~:text=The%20tyrosine%20kinase%20inhibitor%2C%20imatinib%2C,negative%20and%20improved%20after%20plasma')
10. AnnotationURLCitation(end_index=3697, start_index=3569, title='Neurological complications of new chemotherapy agents - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5761528/#:~:text=Imatinib%20is%20the%20oldest%20of,generation')
11. AnnotationURLCitation(end_index=3833, start_index=3698, title='Neurological complications of new chemotherapy agents - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5761528/#:~:text=since%20emerged%20and%20been%20suggested,generation')
12. AnnotationURLCitation(end_index=4358, start_index=4206, title='The therapeutic potential of vitamin D supplementation in asthma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=match%20at%20L215%20Many%20researchers,such%20as%20B%20cells%2C%20T')
13. AnnotationURLCitation(end_index=4867, start_index=4717, title='Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndrome - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/38085047/#:~:text=Low%20serum%20levels%20of%2025,to%20prevent%20multiple%20sclerosis%20is')
14. AnnotationURLCitation(end_index=5229, start_index=5079, title='Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndrome - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/38085047/#:~:text=Low%20serum%20levels%20of%2025,to%20prevent%20multiple%20sclerosis%20is')
15. AnnotationURLCitation(end_index=5659, start_index=5500, title='Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndrome - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/38085047/#:~:text=Low%20serum%20levels%20of%2025,multiple%20sclerosis%20have%20been%20inconclusive')
16. AnnotationURLCitation(end_index=6251, start_index=6093, title='The therapeutic potential of vitamin D supplementation in asthma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=Many%20researchers%20associate%20vitamin%20D,such%20as%20B%20cells%2C%20T')
17. AnnotationURLCitation(end_index=6785, start_index=6669, title='Vitamin D and Neurological Diseases: An Endocrine View - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5713448/#:~:text=PMC%20pmc,29%5D%2C%20it%20should')
18. AnnotationURLCitation(end_index=7600, start_index=7450, title='The therapeutic potential of vitamin D supplementation in asthma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=Interestingly%2C%20patients%20with%20vitamin%20D,25%20%2C%20%2029')
19. AnnotationURLCitation(end_index=7901, start_index=7751, title='The therapeutic potential of vitamin D supplementation in asthma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=Interestingly%2C%20patients%20with%20vitamin%20D,25%20%2C%20%2029')
20. AnnotationURLCitation(end_index=8263, start_index=8126, title='The therapeutic potential of vitamin D supplementation in asthma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=Alvin%20et%20al.%20,mean%20age%20of%20the%20patients')
21. AnnotationURLCitation(end_index=8656, start_index=8498, title='The therapeutic potential of vitamin D supplementation in asthma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=Many%20researchers%20associate%20vitamin%20D,such%20as%20B%20cells%2C%20T')
22. AnnotationURLCitation(end_index=8797, start_index=8657, title='The therapeutic potential of vitamin D supplementation in asthma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=such%2C%20a%20considerable%20body%20of,25%20%2C%20%2029')
23. AnnotationURLCitation(end_index=9242, start_index=9102, title='The therapeutic potential of vitamin D supplementation in asthma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=asthma%20severity%20%28p%E2%80%89%3D%E2%80%890,6%7D%2Fl')
24. AnnotationURLCitation(end_index=9377, start_index=9243, title='The therapeutic potential of vitamin D supplementation in asthma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=vitamin%20D%20deficiency%20and%20reduced,Of%20the')
25. AnnotationURLCitation(end_index=9664, start_index=9533, title='The therapeutic potential of vitamin D supplementation in asthma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=match%20at%20L439%20asthma%20severity,6%7D%2Fl')
26. AnnotationURLCitation(end_index=9976, start_index=9808, title='The therapeutic potential of vitamin D supplementation in asthma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=match%20at%20L778%20vitamin%20D,especially%20in%20reducing%20asthma%20exacerbations')
27. AnnotationURLCitation(end_index=10138, start_index=9977, title='The therapeutic potential of vitamin D supplementation in asthma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=vitamin%20D%20deficiency,especially%20in%20reducing%20asthma%20exacerbations')
28. AnnotationURLCitation(end_index=10591, start_index=10423, title='The therapeutic potential of vitamin D supplementation in asthma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=match%20at%20L778%20vitamin%20D,especially%20in%20reducing%20asthma%20exacerbations')
29. AnnotationURLCitation(end_index=10753, start_index=10592, title='The therapeutic potential of vitamin D supplementation in asthma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=vitamin%20D%20deficiency,especially%20in%20reducing%20asthma%20exacerbations')
30. AnnotationURLCitation(end_index=11378, start_index=11228, title='The therapeutic potential of vitamin D supplementation in asthma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=Interestingly%2C%20patients%20with%20vitamin%20D,25%20%2C%20%2029')
31. AnnotationURLCitation(end_index=11519, start_index=11379, title='The therapeutic potential of vitamin D supplementation in asthma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=such%2C%20a%20considerable%20body%20of,25%20%2C%20%2029')
32. AnnotationURLCitation(end_index=12196, start_index=12068, title='CNS demyelination after initiating the tyrosine kinase inhibitor imatinib: A report of two cases - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/31845621/#:~:text=stroke,negative%20and%20improved%20after%20plasma')
33. AnnotationURLCitation(end_index=12408, start_index=12292, title='CNS demyelination after initiating the tyrosine kinase inhibitor imatinib: A report of two cases - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/31845621/#:~:text=in%20clinical%20trials%20as%20a,cells')
34. AnnotationURLCitation(end_index=12705, start_index=12572, title='CNS demyelination after initiating the tyrosine kinase inhibitor imatinib: A report of two cases - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/31845621/#:~:text=neuritis%20with%20magnetic%20resonance%20imaging,cells')
35. AnnotationURLCitation(end_index=12905, start_index=12771, title='Neurological complications of new chemotherapy agents - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5761528/#:~:text=3%20%29,used%20in%20conjunction%20with%20classical')
36. AnnotationURLCitation(end_index=13270, start_index=13096, title='CNS demyelination after initiating the tyrosine kinase inhibitor imatinib: A report of two cases - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/31845621/#:~:text=The%20tyrosine%20kinase%20inhibitor%2C%20imatinib%2C,negative%20and%20improved%20after%20plasma')
37. AnnotationURLCitation(end_index=13864, start_index=13736, title='Neurological complications of new chemotherapy agents - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5761528/#:~:text=Imatinib%20is%20the%20oldest%20of,generation')
38. AnnotationURLCitation(end_index=14000, start_index=13865, title='Neurological complications of new chemotherapy agents - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5761528/#:~:text=since%20emerged%20and%20been%20suggested,generation')
39. AnnotationURLCitation(end_index=14386, start_index=14223, title='Neurological complications of new chemotherapy agents - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5761528/#:~:text=for%20patients%20with%20chronic%20myeloid,been%20rarely%20implicated%20with%20a')
40. AnnotationURLCitation(end_index=15304, start_index=15154, title='Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndrome - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/38085047/#:~:text=Low%20serum%20levels%20of%2025,to%20prevent%20multiple%20sclerosis%20is')
41. AnnotationURLCitation(end_index=15634, start_index=15462, title='The 2023’s Growing Evidence Confirming the Relationship between Vitamin D and Autoimmune Diseases - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10675822/#:~:text=The%202023%E2%80%99s%20Growing%20Evidence%20Confirming,of%20the%20disease%2C%20but%20of')
42. AnnotationURLCitation(end_index=15810, start_index=15635, title='The 2023’s Growing Evidence Confirming the Relationship between Vitamin D and Autoimmune Diseases - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10675822/#:~:text=In%20relapsing%E2%80%93remitting%20MS%2C%20a%20systematic,of%20the%20disease%2C%20but%20of')
43. AnnotationURLCitation(end_index=16149, start_index=15977, title='The 2023’s Growing Evidence Confirming the Relationship between Vitamin D and Autoimmune Diseases - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10675822/#:~:text=The%202023%E2%80%99s%20Growing%20Evidence%20Confirming,of%20the%20disease%2C%20but%20of')
44. AnnotationURLCitation(end_index=16746, start_index=16630, title='Vitamin D and Neurological Diseases: An Endocrine View - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5713448/#:~:text=PMC%20pmc,29%5D%2C%20it%20should')
45. AnnotationURLCitation(end_index=16890, start_index=16747, title='Vitamin D and Neurological Diseases: An Endocrine View - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5713448/#:~:text=As%20summarized%20in%20Figure%201%2C,29%5D%2C%20it%20should')
46. AnnotationURLCitation(end_index=17541, start_index=17379, title='Off‑target effect of imatinib and nilotinib on human vitamin D3 metabolism - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/29115640/#:~:text=demonstrated%20a%204%E2%80%91fold%20increase,to%20their%20metabolism%20by%20CYP27B1')
47. AnnotationURLCitation(end_index=17853, start_index=17691, title='Off‑target effect of imatinib and nilotinib on human vitamin D3 metabolism - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/29115640/#:~:text=demonstrated%20a%204%E2%80%91fold%20increase,to%20their%20metabolism%20by%20CYP27B1')
48. AnnotationURLCitation(end_index=18127, start_index=17959, title='Off‑target effect of imatinib and nilotinib on human vitamin D3 metabolism - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/29115640/#:~:text=an%20intracellular%20accumulation%20of%20calcidiol,to%20their%20metabolism%20by%20CYP27B1')
49. AnnotationURLCitation(end_index=18607, start_index=18457, title='Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndrome - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/38085047/#:~:text=Low%20serum%20levels%20of%2025,to%20prevent%20multiple%20sclerosis%20is')
50. AnnotationURLCitation(end_index=19017, start_index=18855, title='Off‑target effect of imatinib and nilotinib on human vitamin D3 metabolism - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/29115640/#:~:text=demonstrated%20a%204%E2%80%91fold%20increase,to%20their%20metabolism%20by%20CYP27B1')
51. AnnotationURLCitation(end_index=19840, start_index=19706, title='The therapeutic potential of vitamin D supplementation in asthma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=vitamin%20D%20deficiency%20and%20reduced,Of%20the')
52. AnnotationURLCitation(end_index=19981, start_index=19841, title='The therapeutic potential of vitamin D supplementation in asthma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=asthma%20severity%20%28p%E2%80%89%3D%E2%80%890,6%7D%2Fl')
53. AnnotationURLCitation(end_index=20315, start_index=20208, title='The therapeutic potential of vitamin D supplementation in asthma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=gestation,Wagner%20and')
54. AnnotationURLCitation(end_index=20507, start_index=20387, title='The therapeutic potential of vitamin D supplementation in asthma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=match%20at%20L33%20vitamin%20D,term')
55. AnnotationURLCitation(end_index=20662, start_index=20508, title='The therapeutic potential of vitamin D supplementation in asthma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=airway%20injury%20and%20can%20decrease,However%2C%20further%20studies')
56. AnnotationURLCitation(end_index=20975, start_index=20844, title='The therapeutic potential of vitamin D supplementation in asthma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=match%20at%20L439%20asthma%20severity,6%7D%2Fl')
57. AnnotationURLCitation(end_index=21247, start_index=21082, title='The therapeutic potential of vitamin D supplementation in asthma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=%5B154%5D%20%5B156%5D%20CTRI%2F2018%2F07%2F014777%20%20,vitamin%20D%20deficiency')
58. AnnotationURLCitation(end_index=21943, start_index=21782, title='The therapeutic potential of vitamin D supplementation in asthma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=between%20serum%20vitamin%20D%20concentration,However%2C%20further%20studies')
59. AnnotationURLCitation(end_index=22102, start_index=21944, title='The therapeutic potential of vitamin D supplementation in asthma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=Many%20researchers%20associate%20vitamin%20D,such%20as%20B%20cells%2C%20T')
60. AnnotationURLCitation(end_index=22625, start_index=22475, title='The therapeutic potential of vitamin D supplementation in asthma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=Interestingly%2C%20patients%20with%20vitamin%20D,25%20%2C%20%2029')
61. AnnotationURLCitation(end_index=23176, start_index=23026, title='The therapeutic potential of vitamin D supplementation in asthma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=Interestingly%2C%20patients%20with%20vitamin%20D,25%20%2C%20%2029')
62. AnnotationURLCitation(end_index=23317, start_index=23177, title='The therapeutic potential of vitamin D supplementation in asthma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=such%2C%20a%20considerable%20body%20of,25%20%2C%20%2029')
63. AnnotationURLCitation(end_index=24365, start_index=24212, title='KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/28514613/#:~:text=Results%3A%20Among%20the%2062%20patients,than%20in%20the%20placebo%20group')
64. AnnotationURLCitation(end_index=24507, start_index=24366, title='KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/28514613/#:~:text=Conclusions%3A%20In%20patients%20with%20severe,These%20results')
65. AnnotationURLCitation(end_index=24788, start_index=24649, title='KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/28514613/#:~:text=placebo%20group%20%28P%3D0,than%20in%20the%20placebo%20group')
66. AnnotationURLCitation(end_index=25113, start_index=24993, title='Imatinib - StatPearls - NCBI Bookshelf', type='url_citation', url='https://www.ncbi.nlm.nih.gov/books/NBK551676/#:~:text=,imatinib%20causing%20SJS%20is%20unclear')
67. AnnotationURLCitation(end_index=26243, start_index=26115, title='CNS demyelination after initiating the tyrosine kinase inhibitor imatinib: A report of two cases - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/31845621/#:~:text=stroke,negative%20and%20improved%20after%20plasma')
68. AnnotationURLCitation(end_index=27479, start_index=27345, title='Neurological complications of new chemotherapy agents - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5761528/#:~:text=3%20%29,used%20in%20conjunction%20with%20classical')
69. AnnotationURLCitation(end_index=27867, start_index=27751, title='CNS demyelination after initiating the tyrosine kinase inhibitor imatinib: A report of two cases - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/31845621/#:~:text=in%20clinical%20trials%20as%20a,cells')
70. AnnotationURLCitation(end_index=28212, start_index=28092, title='Imatinib - StatPearls - NCBI Bookshelf', type='url_citation', url='https://www.ncbi.nlm.nih.gov/books/NBK551676/#:~:text=,imatinib%20causing%20SJS%20is%20unclear')
71. AnnotationURLCitation(end_index=29641, start_index=29473, title='The therapeutic potential of vitamin D supplementation in asthma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=match%20at%20L778%20vitamin%20D,especially%20in%20reducing%20asthma%20exacerbations')
72. AnnotationURLCitation(end_index=29803, start_index=29642, title='The therapeutic potential of vitamin D supplementation in asthma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=vitamin%20D%20deficiency,especially%20in%20reducing%20asthma%20exacerbations')
73. AnnotationURLCitation(end_index=30534, start_index=30372, title='Off‑target effect of imatinib and nilotinib on human vitamin D3 metabolism - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/29115640/#:~:text=demonstrated%20a%204%E2%80%91fold%20increase,to%20their%20metabolism%20by%20CYP27B1')
74. AnnotationURLCitation(end_index=30712, start_index=30581, title='KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/28514613/#:~:text=marker%20of%20mast,than%20in%20the%20placebo%20group')
75. AnnotationURLCitation(end_index=31111, start_index=30938, title='Changes in bone metabolic parameters in children with chronic myeloid leukemia on imatinib treatment - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3560809/#:~:text=Discussion%20This%20study%20is%20the,hypophosphatemia%20and%20a%20compensatory%20increase')
76. AnnotationURLCitation(end_index=31292, start_index=31112, title='Changes in bone metabolic parameters in children with chronic myeloid leukemia on imatinib treatment - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3560809/#:~:text=metabolic%20markers%20in%20children%20under,hypophosphatemia%20and%20a%20compensatory%20increase')
77. AnnotationURLCitation(end_index=32162, start_index=32009, title='KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/28514613/#:~:text=Results%3A%20Among%20the%2062%20patients,than%20in%20the%20placebo%20group')
78. AnnotationURLCitation(end_index=32304, start_index=32163, title='KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/28514613/#:~:text=Conclusions%3A%20In%20patients%20with%20severe,These%20results')
79. AnnotationURLCitation(end_index=32583, start_index=32452, title='KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/28514613/#:~:text=marker%20of%20mast,than%20in%20the%20placebo%20group')
80. AnnotationURLCitation(end_index=33341, start_index=33213, title='CNS demyelination after initiating the tyrosine kinase inhibitor imatinib: A report of two cases - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/31845621/#:~:text=stroke,negative%20and%20improved%20after%20plasma')
81. AnnotationURLCitation(end_index=33804, start_index=33676, title='Neurological complications of new chemotherapy agents - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5761528/#:~:text=Imatinib%20is%20the%20oldest%20of,generation')
82. AnnotationURLCitation(end_index=33940, start_index=33805, title='Neurological complications of new chemotherapy agents - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5761528/#:~:text=since%20emerged%20and%20been%20suggested,generation')
83. AnnotationURLCitation(end_index=34240, start_index=34077, title='Neurological complications of new chemotherapy agents - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5761528/#:~:text=for%20patients%20with%20chronic%20myeloid,been%20rarely%20implicated%20with%20a')
84. AnnotationURLCitation(end_index=34903, start_index=34766, title='The therapeutic potential of vitamin D supplementation in asthma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=Alvin%20et%20al.%20,mean%20age%20of%20the%20patients')
85. AnnotationURLCitation(end_index=35170, start_index=35029, title='The therapeutic potential of vitamin D supplementation in asthma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=participants%20with%20vitamin%20D%20deficiency,vs.%20100')
86. AnnotationURLCitation(end_index=35621, start_index=35494, title='The therapeutic potential of vitamin D supplementation in asthma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=match%20at%20L697%20gestation,Wagner%20and')
87. AnnotationURLCitation(end_index=35790, start_index=35622, title='The therapeutic potential of vitamin D supplementation in asthma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=match%20at%20L778%20vitamin%20D,especially%20in%20reducing%20asthma%20exacerbations')
88. AnnotationURLCitation(end_index=36148, start_index=35995, title='Frontiers | A Meta-Analysis on Vitamin D Supplementation and Asthma Treatment', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fnut.2022.860628/full#:~:text=Frontiers%20%7C%20A%20Meta,of%20FEV1%20baseline.%20In')
89. AnnotationURLCitation(end_index=36725, start_index=36572, title='KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/28514613/#:~:text=Results%3A%20Among%20the%2062%20patients,than%20in%20the%20placebo%20group')
90. AnnotationURLCitation(end_index=36925, start_index=36772, title='KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/28514613/#:~:text=Results%3A%20Among%20the%2062%20patients,than%20in%20the%20placebo%20group')
91. AnnotationURLCitation(end_index=37255, start_index=37104, title='KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/28514613/#:~:text=doses%20in%20the%20imatinib%20group%2C,than%20in%20the%20placebo%20group')
92. AnnotationURLCitation(end_index=37474, start_index=37335, title='KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/28514613/#:~:text=placebo%20group%20%28P%3D0,than%20in%20the%20placebo%20group')
93. AnnotationURLCitation(end_index=37732, start_index=37601, title='KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/28514613/#:~:text=marker%20of%20mast,than%20in%20the%20placebo%20group')
94. AnnotationURLCitation(end_index=38012, start_index=37881, title='KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/28514613/#:~:text=marker%20of%20mast,than%20in%20the%20placebo%20group')
95. AnnotationURLCitation(end_index=38848, start_index=38698, title='Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndrome - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/38085047/#:~:text=Low%20serum%20levels%20of%2025,to%20prevent%20multiple%20sclerosis%20is')
96. AnnotationURLCitation(end_index=39360, start_index=39185, title='The 2023’s Growing Evidence Confirming the Relationship between Vitamin D and Autoimmune Diseases - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10675822/#:~:text=In%20relapsing%E2%80%93remitting%20MS%2C%20a%20systematic,of%20the%20disease%2C%20but%20of')
97. AnnotationURLCitation(end_index=40282, start_index=40154, title='CNS demyelination after initiating the tyrosine kinase inhibitor imatinib: A report of two cases - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/31845621/#:~:text=stroke,negative%20and%20improved%20after%20plasma')
98. AnnotationURLCitation(end_index=40613, start_index=40463, title='Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndrome - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/38085047/#:~:text=Low%20serum%20levels%20of%2025,to%20prevent%20multiple%20sclerosis%20is')
99. AnnotationURLCitation(end_index=40843, start_index=40681, title='Off‑target effect of imatinib and nilotinib on human vitamin D3 metabolism - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/29115640/#:~:text=demonstrated%20a%204%E2%80%91fold%20increase,to%20their%20metabolism%20by%20CYP27B1')
100. AnnotationURLCitation(end_index=41072, start_index=40922, title='The therapeutic potential of vitamin D supplementation in asthma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=Interestingly%2C%20patients%20with%20vitamin%20D,25%20%2C%20%2029')
101. AnnotationURLCitation(end_index=41331, start_index=41200, title='The therapeutic potential of vitamin D supplementation in asthma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=match%20at%20L439%20asthma%20severity,6%7D%2Fl')
102. AnnotationURLCitation(end_index=41859, start_index=41706, title='KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/28514613/#:~:text=Results%3A%20Among%20the%2062%20patients,than%20in%20the%20placebo%20group')
103. AnnotationURLCitation(end_index=42001, start_index=41860, title='KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/28514613/#:~:text=Conclusions%3A%20In%20patients%20with%20severe,These%20results')
104. AnnotationURLCitation(end_index=44488, start_index=44338, title='The therapeutic potential of vitamin D supplementation in asthma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12241240/#:~:text=Interestingly%2C%20patients%20with%20vitamin%20D,25%20%2C%20%2029')
105. AnnotationURLCitation(end_index=44642, start_index=44489, title='KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/28514613/#:~:text=Results%3A%20Among%20the%2062%20patients,than%20in%20the%20placebo%20group')